.
MergerLinks Header Logo

New Deal


Announced

Keensight Capital-backed Symeres to acquire Exemplify BioPharma.

Synopsis

Keensight Capital-backed Symeres, a global drug discovery company, agreed to acquire Exemplify BioPharma, a pharmaceutical company. FInancial terms were not disclosed. “We are proud to see Exemplify BioPharma’s scientific expertise and strategic location in North America recognized and become part of the Symeres family. Symeres is a trusted partner that shares our values and business philosophy of strong customer focus. Exemplify BioPharma’s recent move to our new and larger state-of-the-art facility, and the combination with a global business like Symeres, will allow us to better serve our clients under one roof. We look forward to accelerating our growth together,” Yadan Chen, Exemplify BioPharma CEO.

Show Details & Financials

Market Context

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US